Tibet Duo Rui Pharmaceutical Co

Tibet Duo Rui Pharmaceutical Co ROA

The Return on Assets (ROA) of Tibet Duo Rui Pharmaceutical Co (301075.SZ) as of Oct 28, 2026 is -7.96 %. In the previous year, Return on Assets (ROA) was -4.08 % — a change of 95.03% (lower).

ROA

-7.96 %

YoY

95.03%

Last updated:

In 2025, Tibet Duo Rui Pharmaceutical Co's return on assets (ROA) was -7.96 %, a 95.03% increase from the -4.08 % ROA in the previous year.

The Tibet Duo Rui Pharmaceutical Co ROA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

ROA
Date
ROA
Jan 1, 2018
18.46 CNY
Jan 1, 2019
24.37 CNY
Jan 1, 2020
24.66 CNY
Jan 1, 2021
8.05 CNY
Jan 1, 2022
2.28 CNY
Jan 1, 2023
1.76 CNY
Jan 1, 2024
-4.08 CNY
Jan 1, 2025
-7.96 CNY
The Tibet Duo Rui Pharmaceutical Co ROA history
YEARROAYoY
-7.96 %+95.03%
-4.08 %-332.22%
1.76 %-22.92%
2.28 %-71.65%
8.05 %-67.38%
24.66 %+1.21%
24.37 %+32.02%
18.46 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Tibet Duo Rui Pharmaceutical Co Stock analysis

What does Tibet Duo Rui Pharmaceutical Co do? Tibet Duo Rui Pharmaceutical Co., Ltd. generates revenue through the research, development, manufacture, and sale of chemical preparations and their raw materials. The company's core product, sodium acetate ringer injection, is used for supplementing body fluids, regulating electrolyte balance, and correcting acidosis. Additional products include compound electrolyte injection, compound mannitol injection, and cefotaxime sodium for injection, which are sold to healthcare providers and hospitals. The firm targets the pharmaceutical market segment focused on fluid and electrolyte management and antibiotic treatments. The company's revenue streams are derived from the sale of its proprietary chemical preparations, with sodium acetate ringer injection representing a key product line. Compound electrolyte injection and compound mannitol injection cater to specific medical needs, while cefotaxime sodium for injection serves as an antibiotic solution. These products are distributed to hospitals and healthcare facilities within China's pharmaceutical distribution network. Tibet Duo Rui Pharmaceutical's business model centers on developing and commercializing specialized injectable solutions for clinical use. The firm's product portfolio addresses critical healthcare requirements, including fluid replacement, electrolyte regulation, and infection treatment. Sales are directed toward medical institutions that require these specialized pharmaceutical products for patient care. Tibet Duo Rui Pharmaceutical Co is one of the most popular companies on Eulerpool.

ROA Details

Understanding Tibet Duo Rui Pharmaceutical Co's Return on Assets (ROA)

Tibet Duo Rui Pharmaceutical Co's Return on Assets (ROA) is a key performance indicator that measures the company's profitability in relation to its total assets. It is calculated by dividing the net income by the total assets. A higher ROA indicates efficient asset utilization to generate profits, reflecting managerial effectiveness and financial health.

Year-to-Year Comparison

Comparing Tibet Duo Rui Pharmaceutical Co's ROA year-over-year provides insights into the company’s operational efficiency and asset utilization trends. An increasing ROA demonstrates enhanced asset efficiency and profitability, while a declining ROA can indicate operational or financial challenges.

Impact on Investments

Investors consider Tibet Duo Rui Pharmaceutical Co's ROA as a crucial metric to evaluate the company’s profitability and efficiency. A higher ROA signifies that the company is effectively utilizing its assets to generate profits, making it a potentially attractive investment.

Interpreting ROA Fluctuations

Variations in Tibet Duo Rui Pharmaceutical Co’s ROA can be attributed to changes in net income, asset purchases, or operational efficiencies. Analyzing these fluctuations assists in assessing the company's financial performance, management efficiency, and strategic financial positioning.

Frequently Asked Questions about Tibet Duo Rui Pharmaceutical Co stock

Return on Assets (ROA) of Tibet Duo Rui Pharmaceutical Co is -7.96 % in 2025.

Return on Assets (ROA) of Tibet Duo Rui Pharmaceutical Co changed from -4.08 % to -7.96 %, representing a 95.03% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Return on Assets (ROA) Tibet Duo Rui Pharmaceutical Co since 2006 – with annual values, charts, and detailed analysis.

Return on Assets, also known as ROA, is a financial metric used to measure a company's profitability. It is used to determine how effectively a company uses its assets to generate profits. It is also referred to as the ratio of net income to total assets. ROA is an important indicator of a company's overall financial performance as it measures the company's ability to generate more profit from the assets it employs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Return on Assets (ROA)'s Tibet Duo Rui Pharmaceutical Co with sector peers and the industry average to assess whether it is attractive.

To evaluate Return on Assets (ROA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Return on Assets (ROA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Profitability — Tibet Duo Rui Pharmaceutical Co

ROEROAROCEROICAsset TurnoverInventory TurnoverReceivables TurnoverDays Sales OutstandingDays Inventory OutstandingDays Payable OutstandingCash Conversion CycleCROICGross Profit/AssetsFixed Asset TurnoverEquity TurnoverWorking Capital TurnoverPayables TurnoverCapital IntensityReceivables/RevenueInventory/RevenueEBIT/Assets

All Key Metrics — Tibet Duo Rui Pharmaceutical Co